glp 1 agonist news Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care JDD in the News: Skin
Description
In particular, Frssing et al
Subgroup analyses were performed for trials using different molecules, in the hypothesis that effects on cancer could be drugspecific, rather than common to the whole class
doi: 10.1177/1403494818764810 [DOI] [PubMed] [Google Scholar] 6.Henney AE, Wilding JPH, Alam U, Cuthbertson DJ
Heerspink HJ, Jongs N, Chertow GM, Langkilde AM, McMurray JJ, Correa-Rotter R, et al
In November 2023, AstraZeneca made a potential $2 billion investment in the expanding anti-obesity medical industry by licensing an experimental pill from China's Eccogene ECC5004, which is part of a class of extremely efficient weight-loss medicines known as GLP-1 receptor agonists in current injectable therapies
Rubino, M
